Hormone therapy and stroke

Clinical Obstetrics and Gynecology

Volumn 51, Issue 3, 2008, Pages 581-591

  Birge, Stanley J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hormone therapy; Menopause; Stroke

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE;

ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MENOPAUSE; PATHOGENESIS; PRIMARY PREVENTION; RISK REDUCTION; STROKE; TREATMENT DURATION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; AGED; ESTROGEN THERAPY; FEMALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT;

AGED; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK ASSESSMENT; STROKE;

EID: 54449097702     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318181df30     Document Type: Article

References (55)

1. Bushnell CD, Hurn P, Colton C, et al. Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke. 2006;37:2387-2399.
2. Gresham GE, Fitzpatrick TE, Wolf PA, et al. Residual disability in survivors of stroke - the Framingham study. N Engl J Med. 1975;293:954-956.
3. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
4. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
5. Bonita R. Epidemiology of stroke. Lancet. 1992;339:342-344.
6. Ask-Upmark E. Life and death without ovaries. Acta Med Scand. 1962;172: 129-135.
7. Shah S, Bell RJ, Davis SR. Homocysteine, estrogen and cognitive decline. Climacteric. 2006;9:77-87.
8. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxford). 2005;62:265-281.
9. Wilkins CH, Sheline YI, Roe CM, et al. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006;14:1032-1040.
10. Duque G, El Abdaimi K, Macoritto M, et al. Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation. Biochem Biophys Res Commun. 2002;299: 446-454.
11. Kaya E, Sahin FK, Koken G, et al. Acute effect of intranasal estrogen on cerebral and cerebellar perfusion in postmenopausal women. Maturitas. 2008;59:72-82.
12. Funk JL, Mortel KF, Meyer JS.Effects of estrogen replacement therapy on cerebral perfusion and cognition among post-menopausal women. Dementia. 1991;2: 268-272.
13. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336: 1769-1775.
14. GrodsteinF,Stampfer MJ, FalkebornM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology. 1999;10:476-480.
15. Pedersen AT, Lidegaard O, Kreiner S, et al. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350: 1277-1283.
16. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080-1086.
17. Schairer C, Adami HO, Hoover R, et al. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology. 1997;8:59-65.
18. Simon JA, Hsia J, Cauley JA, et al. Post-menopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-642.
19. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349:523-534.
20. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289: 2673-2684.
21. Salpeter SR, Walsh JM, Greyber E, et al. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A metaanalysis. J Gen Intern Med. 2006;21: 363-366.
22. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297:1465-1477.
23. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronaryartery calcification. N Engl J Med. 2007; 356:2591-2602.
24. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
25. Yeboah J, Reboussin DM, Waters D, et al. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J. 2007;153:439-444.
26. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308: 1583-1587.
27. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002; 105:2962-2967.
28. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
29. Lokkegaard E, Jovanovic Z, Heitmann BL, et al. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study. Arch Neurol. 2003;60:1379-1384.
30. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
31. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005;162:404-414.
32. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol. 2006;163:589-599.
33. Lemaitre RN, Weiss NS, Smith NL, et al. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med. 2006;166:399-404.
34. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ. 2005;330:342.
35. Magliano DJ, Rogers SL, Abramson MJ, et al. Hormone therapy and cardiovascular disease: a systematic review and metaanalysis. BJOG. 2006;113:5-14.
36. Arana A, Varas C, Gonzalez-Perez A, et al. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause. 2006;13: 730-736.
37. Stanczyk FZ. Parenteral versus oral treatment of postmenopausal women with estrogen. Menopause. 2007;14:968-970.
38. Bhavnani BR, Nisker JA, Martin J, et al. Comparison of pharmacokinetics of a conjugated equine estrogen preparation (Premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. J Soc Gynecol Investig. 2000;7: 175-183.
39. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292:1581-1587.
40. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003;23: 1116-1121.
41. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost. 2007;97: 558-565.
42. CanonicoM, Oger E, Plu-Bureau G, etal. Hormone therapy and venous throm-boembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115: 840-845.
43. Eilertsen AL, Qvigstad E, Andersen TO, et al. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas. 2006;55: 278-287.
44. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and trans-dermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-432.
45. Smith NL, Heckbert SR, Lemaitre RN, et al. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Arterioscler Thromb Vasc Biol. 2006;26:2807-2812.
46. Mueck AO, Genazzani AR, Samsioe G, et al. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause. 2007;14:978-984.
47. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166-170.
48. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290: 2945-2951.
49. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
50. Carr BR, Khan N, Adams-Huet B, et al. Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. Fertil Steril. 2006;85: 667-673.
51. Prestwood KM, Unson C, Kulldorff M, et al. The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci. 2004;59:827-832.
52. Vongpatanasin W, Tuncel M, Wang Z, et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmeno-pausal women. J Am Coll Cardiol. 2003; 41:1358-1363.
53. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
54. Curb JD, Prentice RL, Bray PF, et al. Venousthrombosis and conjugatedequine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-780.
55. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.